Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.

@article{Kohno2007LinezolidVV,
  title={Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.},
  author={Shigeru Kohno and Keizo Yamaguchi and Naoki Aikawa and Yoshinobu Sumiyama and Shigeki Odagiri and Nobumasa Aoki and Yoshito Niki and Shinichi Watanabe and Masutaka Furue and Tetsuya Ito and Rodney Victor Croos-Dabrera and Kenneth J. Tack},
  journal={The Journal of antimicrobial chemotherapy},
  year={2007},
  volume={60 6},
  pages={1361-9}
}
OBJECTIVES To compare the efficacy and safety of linezolid and vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in Japan. METHODS Patients with nosocomial pneumonia, complicated skin and soft-tissue infections or sepsis caused by MRSA were randomized to receive linezolid (600 mg every 12 h) or vancomycin (1 g every 12 h). RESULTS One hundred patients received linezolid and 51 received vancomycin with outcomes evaluated at the end of therapy (EOT… CONTINUE READING